Author(s): Devidas A. Batule, Sanchita J. Borate, Neha N. Mahanawar, Avinash S. Bhosale, Manoj B. Shinde, Nikhil J. Salunkhe, Bhushan R. Pawar

Email(s): bhosalea1@gmail.com

DOI: 10.52711/0974-360X.2026.00242   

Address: Devidas A. Batule, Sanchita J. Borate, Neha N. Mahanawar, Avinash S. Bhosale*, Manoj B. Shinde, Nikhil J. Salunkhe, Bhushan R. Pawar
Department of Pharmaceutical Chemistry, Satara College of Pharmacy, Satara, Dr. Babasaheb Ambedkar Technological University, Lonere, 415004 Maharashtra, India.
*Corresponding Author

Published In:   Volume - 19,      Issue - 4,     Year - 2026


ABSTRACT:
Since depression is a common mental illness affecting an estimated 5% of people worldwide, investigators are encouraged to develop effective antidepressants. According to the monoamine-deficiency hypothesis, the underlying path physiology of depression is a deficiency of some neurotransmitters (serotonin, nor epinephrine, or dopamine) in the central nervous system. The neurotransmitter serotonin has drawn the most attention concerning depression. That leads to higher life satisfaction, convergent thinking, higher ratings of mindfulness, lower ratings of depression, and anxiety. In this study, we investigated the influences of various plant bioactive compounds which are used as antidepressants Hypericine, Hyperforine, Crocetine, Vitexine and Psilocybin against serotonin and mouse pendrine (anion exchanger) and determined their kinetics. We perform molecular docking study by using Schrödinger software (maestro v 10.2). According to the molecular docking study, Crocetine, Vitexine, Psilocybin which are the most active inhibitors have the glide scores with -6.08kcal/mol, -6.78kcal/mol, -6.55kcal/mol against various serotonin and mouse pendrine anion exchanger, respectively. The binding analysis of the inhibitor-enzyme complexes has revealed that their inhibition mechanisms result from interactions with the critical residue of the catalytic active site to produce novel derivatives. According to our findings, these compounds have good receptor binding affinity, with Crocetine, Vitexine, and Psilocybin having the highest binding affinity.


Cite this article:
Devidas A. Batule, Sanchita J. Borate, Neha N. Mahanawar, Avinash S. Bhosale, Manoj B. Shinde, Nikhil J. Salunkhe, Bhushan R. Pawar. Unveiling the Interactions: Molecular Docking of Antidepressants with Human SERT and Mouse Pendrin. Research Journal of Pharmacy and Technology. 2026;19(4):1688-2. doi: 10.52711/0974-360X.2026.00242

Cite(Electronic):
Devidas A. Batule, Sanchita J. Borate, Neha N. Mahanawar, Avinash S. Bhosale, Manoj B. Shinde, Nikhil J. Salunkhe, Bhushan R. Pawar. Unveiling the Interactions: Molecular Docking of Antidepressants with Human SERT and Mouse Pendrin. Research Journal of Pharmacy and Technology. 2026;19(4):1688-2. doi: 10.52711/0974-360X.2026.00242   Available on: https://rjptonline.org/AbstractView.aspx?PID=2026-19-4-31


REFERENCES: 
1.    Vanden Bosch, G.R. APA Dictionary of Psychology, 2nd ed.; American Psychological Association: Washington, DC, USA, 2015.
2.    Pavithra H Dave, V. Vishnupriya, R. Gayathri. Herbal Remedies for Anxiety and Depression- A Review. Research J. Pharm. and Tech. 2016; 9(8): 1253-1256. doi: 10.5958/0974-360X.2016.00237.7
3.    Fava, M.; Kendler, K.S. Major Depressive Disorder. Neuron 2000, 28, 335–334. DOI: 10.1016/S0092-8674(00)00104-6
4.    Judd, L. Mood disorders in the general population represent an important and worldwide public health problem. Int. J. Clin. Psychopharm. 1995, 10 (suppl 4), 5–10. DOI: 10.1097/00004850-199500104-00002
5.    Donoghue, J.M.; Tylee, A. The treatment of depression: prescribing patterns of antidepressants in primary care in the UK. Br. J. Psych. 1996, 168, 164–168. DOI: 10.1192/bjp.168.2.164
6.    Richelson, E. Pharmacology of antidepressants—characteristic of the ideal drug. Mayo Clin. Proc. 1994, 69, 1069–1081. DOI: 10.1016/S0025-6196(11)62923-3
7.    Demyttenaere, K. Compliance during treatment with antidepressants. J. Affect. Disord. 1997, 43, 27–39. DOI: 10.1016/S0165-0327(96)00115-4
8.    Mulinari, S. Monoamine Theories of Depression: Historical Impact on Biomedical Research. J. Hist. Neurosci. 2012, 21, 366–392. DOI: 10.1080/09637425.2012.695811
9.    Blier, P. Neurotransmitter Targeting in the Treatment of Depression. J. Clin. Psychiatry 2013, 74, 19–24. DOI: 10.4088/JCP.12r08122
10.    Delgado, P.L. Depression: The case for a monoamine deficiency. J. Clin. Psychiatry 2000, 61 (Suppl. 6), 7–11.
11.    Arroll, B.; Chin, W.Y.; Martis, W.; Goodyear-Smith, F.; Mount, V.; Kingsford, D.; Humm, S.; Blashki, G.; Macgillivray, S. Antidepressants for treatment of depression in primary care: A systematic review and meta-analysis. J. Prim. Health Care 2016, 8, 325–334. DOI: 10.1071/HC15189
12.    Iyer, R.N.; Favela, D.; Zhang, G.; Olson, D.E. The Iboga Enigma: The Chemistry and Neuropharmacology of Iboga Alkaloids and Related Analogs. Nat. Prod. Rep. 2021, 38, 307–329. DOI: 10.1039/D0NP00067K
13.    David, D.J.; Gourion, D. Antidépresseurs et tolérance: Déterminants et prise en charge des principaux effets indésirables. Encéphale 2016, 42, 553–561. DOI: 10.1016/j.encep.2015.11.004
14.    Trindade, E.; Menon, D.; Topfer, L.; Coloma, C. Adverse Effects Associated with Selective Serotonin Reuptake Inhibitors and Tricyclic Antidepressants: A Meta-Analysis. CMAJ 1998, 10, 1245–1252.
15.    Foong, A.-L.; Grindrod, K.A.; Patel, T.; Kellar, J. Démystifier le Syndrome (ou la Toxicité) Sérotoninergique. Can. Fam. Physician 2018, 64, e422–e430.
16.    Shilyansky, C. Effect of Antidepressant Treatment on Cognitive Impairments Associated with Depression: A Randomised Longitudinal Study. Lancet Psychiatry. 2016, 3, 425–435. DOI: 10.1016/S2215-0366(16)00046-2
17.    McConkey, B.J.; Sobolev, V.; Edelman, M. The performance of current methods in ligand-protein docking. Curr. Sci. 2002, 83, 845–855.
18.    Bhosale, A. S., Sonone, S. D., Sonone, S. M., and Wagh, H. R. An Integrated Molecular Docking Study of Marine Bioactive compound as promising drug candidate against SARS CoV-2 receptor in complex with Antibody. Research Journal of Pharmacy and Technology. 2023; 16(8): 3805-3808.
19.    Bhosale, A., Kokate, A., Jarag, S., Bhise, M., Wagh, V., Chandra, P., and Choudante, S. Targeting COVID-19 through active phytochemicals of betel plant by molecular docking. Int. J. Exp. Res. Rev, 2023, 32, 178-187.
20.    Wagh, H., Bhosale, A., Girbane, V., Bhosale, S., Bhise, M., Deshpande, M., and Ranjan, R. Popping balls papaya extract: Preparation of pediatric dosages in therapeutic formulations for therapeutic usage in dengue and malaria. Int. J. Exp. Res. Rev, 2023, 32, 188-194.
21.    Deore, S., Tajane, P., Bhosale, A., Thube, U., Wagh, V., Wakale, V., and Tare, H. 2-(3, 4-Dihydroxyphenyl)-5, 7-Dihydroxy-4H-Chromen-4-One Flavones Based Virtual Screening for Potential JAK Inhibitors in Inflammatory Disorders. International Research Journal of Multidisciplinary Scope., 2024; 5(1): 557–567
22.    Tajane, P., Kayande, N., Bhosale, A., Deore, S., Tare, H. Design and Discovery of Silmitasertib-based Drugs as a Potential Casein Kinase II Inhibitor for Cholangiocarcinoma through Hybrid In-silico Ligand-Based Virtual Screening with Molecular Docking Method. International Journal of Drug Delivery Technology., 2023, 13(4), pp. 1514–1519
23.    Parameswari. P, Devika. R. In silico Molecular Docking Studies of Quercetin Compound against Anti-inflammatory and Anticancer Proteins. Research J. Pharm. and Tech. 2019; 12(11):5305-5309. doi: 10.5958/0974-360X.2019.00919.3
24.    Moqbel Ali Moqbel Redhwan, Gitima Deka, Melvin Mariyam Varghese. Synthesis and Molecular docking studies of some new Pyrazoline derivatives for Antimicrobial properties. Research J. Pharm. and Tech. 2020; 13(10):4629-4634. doi: 10.5958/0974-360X.2020.00815.X
25.    Gomathy Subramnian, Kalirajan Rajagopal, Farhath Sherin. Molecular Docking Studies, In silico ADMET Screening of Some Novel Thiazolidine Substituted Oxadiazoles as Sirtuin 3 Activators Targeting Parkinson’s Disease. Research J. Pharm. and Tech. 2020; 13(6): 2708-2714. doi: 10.5958/0974-360X.2020.00482.5
26.    Anjali P, Vimalavathini R. In-silico Molecular Docking of Coumarin and Naphthalene Derivatives from Pyrenacantha volubilis with the Pathological Mediators of Rheumatoid Arthritis. Research Journal of Pharmacy and Technology. 2021; 14(10): 5121-5. doi: 10.52711/0974-360X.2021.00892
27.    Jeyabaskar Suganya, Viswanathan T, Mahendran Radha, Nishandhini Marimuthu. In silico Molecular Docking studies to investigate interactions of natural Camptothecin molecule with diabetic enzymes. Research J. Pharm. and Tech. 2017; 10(9): 2917-2922. doi: 10.5958/0974-360X.2017.00515.7
28.    Muhammad Helmi Nadri, Wan Mohd Nuzul Hakimi Wan Salleh. Molecular Docking Studies of Phytochemicals from Piper Species as Potential Dual Inhibitor of Group X Secreted Phospholipase A2 (SPLA2-X) and Cyclooxygenase-2 (COX-2). Research J. Pharm. and Tech. 2020; 13(5): 2181-2186. doi: 10.5958/0974-360X.2020.00392.3
29.    Padmini R, Sitrarasi R, Razia M. Molecular Docking Studies of Bioactive Compounds from Allium sativum Against EML4-ALK Receptor. Research J. Pharm. and Tech. 2017; 10(11): 3741-3747. doi: 10.5958/0974-360X.2017.00679.5
30.    S. Ramachandran, Vimeshya. N, K. Yokeshwaran, Binoy Varghese Cheriyan, M. Vijey Aanandhi. Molecular Docking Studies as Antidepressant Agents, Synthetic Techniques, Antimicrobial Screening of Azetidine-2-One Derivatives- A Review. Research J. Pharm. and Tech. 2020; 13(11): 5524-5528. doi: 10.5958/0974-360X.2020.00964.6

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.52711/0974-360X 

1.3
2021CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank

Journal Policies & Information


Recent Articles




Tags


Not Available